Perlecan/HSPG2 is an essential ECM component involved in the growth responses of metastatic PC cells to heparin-binding growth factors deposited in local and metastatic microenvironments (Savorè et al., 2005). The gene discussed is HSPG2; the disease is pachyonychia congenita.